Prof Barry is a basic scientist with a long standing interest in the cell and molecular basis of immune tolerance, regulatory T cells and the molecular mechanisms that orchestrate their function. He is leading a program focussed on immunotherapies with projects focused on reducing the costs of cell therapy manufacturing and on developing a novel CAR-T cell targeting a broad range of cancers. He has experience from both academic and Biotech sector training, including working in the discovery research and functional genomics departments of Immunex and AMGEN. He currently heads the Molecular Immunology lab in the Robinson Research institute at the University of Adelaide based at the Women's and Children's Hospital. He is applying multi omics technologies (HiC, ATACseq, RNA Seq, TCR seq, scRNAseq, scATACseq) to connect gentic risk tothe genes it impacts and identify the drivers of immune deviation resulting in islet autoimmunity and insulin dependance. He is theme leader for Immunogenomics in the ENDIA consortium, and is a founding member of the Breakthrough T1D funded Genomics consortium.